

## REVIEW

# Bench-to-bedside review: Carbon dioxide

Gerard Curley<sup>1,2</sup>, John G Laffey<sup>1,2</sup> and Brian P Kavanagh<sup>\*3</sup>

### Abstract

Carbon dioxide is a waste product of aerobic cellular respiration in all aerobic life forms. PaCO<sub>2</sub> represents the balance between the carbon dioxide produced and that eliminated. Hypocapnia remains a common – and generally underappreciated – component of many disease states, including early asthma, high-altitude pulmonary edema, and acute lung injury. Induction of hypocapnia remains a common, if controversial, practice in both adults and children with acute brain injury. In contrast, hypercapnia has traditionally been avoided in order to keep parameters normal. More recently, advances in our understanding of the role of excessive tidal volume has prompted clinicians to use ventilation strategies that result in hypercapnia. Consequently, hypercapnia has become increasingly prevalent in the critically ill patient. Hypercapnia may play a beneficial role in the pathogenesis of inflammation and tissue injury, but may hinder the host response to sepsis and reduce repair. In contrast, hypocapnia may be a pathogenic entity in the setting of critical illness. The present paper reviews the current clinical status of low and high PaCO<sub>2</sub> in the critically ill patient, discusses the insights gained to date from studies of carbon dioxide, identifies key concerns regarding hypocapnia and hypercapnia, and considers the potential clinical implications for the management of patients with acute lung injury.

### Introduction

The partial pressure of CO<sub>2</sub> in the blood (PaCO<sub>2</sub>) represents the balance between CO<sub>2</sub> produced, CO<sub>2</sub> eliminated, and CO<sub>2</sub> (rarely) inspired:

$$\text{PaCO}_2 \propto \frac{\text{CO}_2 \text{ production}}{\text{CO}_2 \text{ elimination}} + \text{inspired [CO}_2\text{]}$$

\*Correspondence: brian.kavanagh@sickkids.ca

<sup>3</sup>Departments of Critical Care Medicine and Anesthesia and the Program in Physiology and Experimental Medicine, The Hospital for Sick Children, University of Toronto, 555 university Avenue, Toronto, ON M5G 1X8, Canada  
Full list of author information is available at the end of the article

For practical purposes, PaCO<sub>2</sub> reflects the rate of CO<sub>2</sub> elimination.

### Prevalence and causes of altered CO<sub>2</sub> tension

There are no common physiological causes of hypercapnia. Historically, uses of CO<sub>2</sub> included elimination of carbon monoxide poisoning, augmentation of cerebral perfusion during carotid endarterectomy, hastening emergence from general anesthesia, and as treatment for retinal artery occlusion.

The commonest reason for hypercapnia in ventilated patients is a reduced tidal volume (V<sub>T</sub>); this situation is termed permissive hypercapnia. Accidental hypercapnia occurs with problems such as circuit misconnections that permit rebreathing. Increased CO<sub>2</sub> production is uncommon, but occurs with hyperpyrexia, shivering, neuroleptic malignant syndrome, heat stroke, thyrotoxicosis or pheochromocytoma.

Indirect calorimetry utilizes whole-body CO<sub>2</sub> production, together with O<sub>2</sub> consumption, to reflect the amount of energy released from substrate oxidation (that is, the oxidation of carbohydrates, lipids and proteins), although it is more accurate at assessing resting energy expenditure. As such, massive carbohydrate oxygenation may contribute to hypercapnia in patients with impaired pulmonary diffusion [1].

Hypocapnia may be physiologic, accidental, or induced (Table 1). In the critically ill patient, hypocapnia can develop with excessive mechanical ventilation or with cardiopulmonary bypass, high-frequency ventilation, or extracorporeal membrane oxygenation. It may be deliberately induced when intracranial pressure [2] – or neonatal pulmonary artery pressure [3] – is elevated.

### Importance of altered CO<sub>2</sub> tension in critical illness Hypercapnia

High V<sub>T</sub> causes, or potentiates, lung injury [4]. Smaller V<sub>T</sub> often leads to elevated PaCO<sub>2</sub>, termed permissive hypercapnia, and is associated with better survival [5,6]. These low-V<sub>T</sub> strategies are not confined to patients with acute lung injury (ALI)/acute respiratory distress syndrome (ARDS); they were first reported successful in severe asthma [7], and attest to the overall safety of hypercapnia. Indeed, hypercapnia in the presence of higher V<sub>T</sub> may independently improve survival [8].

**Table 1. Causes of hypocapnia**

Hypoxemia	Altitude, pulmonary disease
Pulmonary disorders	Pneumonia, interstitial pneumonitis, fibrosis, edema, pulmonary emboli, vascular disease, bronchial asthma, pneumothorax
Cardiovascular system disorders	Congestive heart failure, hypotension
Metabolic disorders	Acidosis (diabetic, renal, lactic), hepatic failure
Central nervous system disorders	Psychogenic/anxiety hyperventilation, central nervous system infection, central nervous system tumors
Drug induced	Salicylates, methylxanthines, $\beta$ -adrenergic agonists, progesterone
Miscellaneous	Fever, sepsis, pain, pregnancy

### Hypocapnia

Hypocapnia is common in several diseases (Table 1; for example, early asthma, high-altitude pulmonary edema, lung injury), is a common acid–base disturbance and a criterion for systemic inflammatory response syndrome [9], and is a prognostic marker of adverse outcome in diabetic ketoacidosis [10]. Hypocapnia – often prolonged – remains common in the management of adult [11] and pediatric [12] acute brain injury.

### Carbon dioxide transport, sensing and molecular response

CO<sub>2</sub> is carried in the blood as HCO<sub>3</sub><sup>-</sup>, in combination with hemoglobin and plasma proteins, and in solution. Inside the cell, CO<sub>2</sub> interacts with H<sub>2</sub>O to produce carbonic acid (H<sub>2</sub>CO<sub>3</sub>), which is in equilibrium with H<sup>+</sup> and HCO<sub>3</sub><sup>-</sup>, a reaction catalyzed by carbonic anhydrase. CO<sub>2</sub> transport into cells is complex, and passive diffusion, specific transporters and rhesus proteins may all be involved.

CO<sub>2</sub> is sensed in central and peripheral neurons. Changes in CO<sub>2</sub> and H<sup>+</sup> are sensed in chemosensitive neurons in the carotid body and in the hindbrain [13,14]. Whether CO<sub>2</sub> or the pH are preferentially sensed is unclear, but the ventilatory response to hypercapnic acidosis (HCA) exceeds that of an equivalent degree of metabolic acidosis [15], suggesting specific CO<sub>2</sub> sensing. Bicarbonate directly activates adenylate cyclase [16], increasing cAMP and activating protein kinase A, opening Ca<sup>2+</sup> channels and permitting influx of Ca<sup>2+</sup> [14]. In the glomus cells of the carotid nucleus, increased CO<sub>2</sub> levels activate Ca<sup>2+</sup> channels independent of the pH [17].

A key molecular mechanism by which hypercapnia may exert its effects, both beneficial and deleterious, is through the NF- $\kappa$ B transcription factor. NF- $\kappa$ B is a major transcription factor that regulates genes responsible for immunity and inflammation, including proinflammatory cytokines. An *in vitro* study has demonstrated that elevated CO<sub>2</sub> levels suppress expression of TNF and other cytokines by pulmonary artery endothelial cells via suppression of NF- $\kappa$ B activation [18]. Furthermore, hypercapnia inhibits pulmonary epithelial wound repair, also via an NF- $\kappa$ B mechanism [19].

### Physiologic effects of CO<sub>2</sub>

The physiologic effects of CO<sub>2</sub> are diverse and incompletely understood, with direct effects often counterbalanced by indirect effects. In addition, the net effect of hypocapnia or hypercapnia may occur as a function of the pH or CO<sub>2</sub> *per se*.

#### Respiratory system

CO<sub>2</sub> is important in matching regional lung ventilation to perfusion. Alveolar CO<sub>2</sub> increases local alveolar ventilation [20] via inhibition of conducting airway tone. Hypercapnia increases pulmonary vascular tone, potentiating hypoxic pulmonary vasoconstriction and further augmenting V/Q matching, but in some cases exacerbating pulmonary hypertension.

Hypocapnia can worsen ventilation–perfusion matching and gas exchange in the lung via a number of mechanisms, including bronchoconstriction [21], reduction in collateral ventilation [22], reduction in parenchymal compliance [23], and attenuation of hypoxic pulmonary vasoconstriction and increased intrapulmonary shunting [24].

#### Central nervous system

CO<sub>2</sub> stimulates ventilation (see above). Peripheral chemoreceptors respond more rapidly than the central neurons, but central chemosensors make a larger contribution to stimulating ventilation. CO<sub>2</sub> increases cerebral blood flow (CBF) by 1 to 2 ml/100 g/minute per 1 mmHg in PaCO<sub>2</sub> [25], an effect mediated by pH rather than by the partial pressure of CO<sub>2</sub>. Hypercapnia elevates both the partial pressure of O<sub>2</sub> in the blood and CBF, and reducing PaCO<sub>2</sub> to 20 to 25 mmHg decreases CBF by 40 to 50% [26]. The effect of CO<sub>2</sub> on CBF is far larger than its effect on the cerebral blood volume. During sustained hypocapnia, CBF recovers to within 10% baseline by 4 hours; and because lowered HCO<sub>3</sub><sup>-</sup> returns the pH towards normal, abrupt normalization of CO<sub>2</sub> results in (net) alkalemia and risks rebound hyperemia.

Hypocapnia increases both neuronal excitability and excitatory (glutamatergic) synaptic transmission, and suppresses GABA-A-mediated inhibition, resulting in increased O<sub>2</sub> consumption and uncoupling of metabolism to CBF [27].

### Cardiovascular system

Hypercapnia directly inhibits cardiac and vascular muscle contractility, effects that are counterbalanced by sympathoadrenal increases in heart rate and contractility, increasing the cardiac output overall [28]. The partial pressure of O<sub>2</sub> in the blood is increased because increased cardiac output coupled with reduced intrapulmonary shunt increases O<sub>2</sub> delivery, and tissue release of O<sub>2</sub> is augmented because hypercapnia and acidemia shift the hemoglobin–O<sub>2</sub> curve rightward. In addition, HCA increases the O<sub>2</sub> tension in both subcutaneous tissues and in the intestinal wall [29].

Indeed, a large body of evidence now attests to the ability of hypercapnia to increase peripheral tissue oxygenation, independently of its effects on cardiac output [30,31]. In experimental polymicrobial sepsis in female sheep, HCA improved tissue oxygenation and reduced lung edema formation more than dobutamine administration [32]. A study in white rabbits ascertained that 150 mmHg was the permissive upper limit of acute hypercapnia with respect to improvement of tissue perfusion and oxygenation [33]. Finally, a further positive effect of HCA on bioenergetics is evident in the form of a reduction in cellular O<sub>2</sub> consumption [34] and hypercapnia induced mitigation of the fall in gut ATP during endotoxemia in rats, pointing to improvement in energy metabolism in this setting. The net impact is thus increased O<sub>2</sub> supply and less demand. In contrast, hypocapnia does the opposite.

### Carbon dioxide – insights from the bench

Experimental studies provide important preclinical information on the effects and mechanisms of action of CO<sub>2</sub>.

#### Acute lung injury

HCA is protective in many models of ALI. Although hypercapnia reduces the severity of overwhelming experimental ventilator-induced lung injury [35], its effects in milder injury are modest [36] and it may not protect in extensive atelectasis [37]. Hypercapnia inhibits hypoxia-induced chronic pulmonary hypertension in adult and newborn rodents [38,39], and protects against chronic neonatal lung injury [40]. The beneficial effects of HCA in such models are increasingly well understood, and include attenuation of lung neutrophil recruitment, pulmonary and systemic cytokine concentrations, cell apoptosis, and O<sub>2</sub>-derived and nitrogen-derived free radical injury.

Concern has been raised regarding the potential for the anti-inflammatory effects of HCA to impair the host response to infection. In early pulmonary infection, this potential impairment does not appear to occur, with HCA reducing the severity of acute-severe *Escherichia*

*coli* pneumonia-induced ALI [41]. In the setting of more established *E. coli* pneumonia, HCA is also protective [42]. Of concern, HCA worsens the severity of prolonged bacterial pneumonia by a mechanism involving reduced bacterial killing [43]. In contrast, HCA reduces the severity of lung injury and hemodynamic compromise caused by cecal ligation and puncture-induced polymicrobial systemic sepsis [44,45]. The effects of HCA in sepsis therefore appear to depend on the duration of infection and on the site of infection. Other potential adverse effects of hypercapnia may include impairment of alveolar epithelial function, leading to reduced edema clearance [46]. Lastly, HCA may delay cellular repair and wound healing [19], slowing recovery and healing following ALI/ARDS.

Hypocapnia increases microvascular permeability and impairs alveolar fluid reabsorption in the isolated rat lung, due to an associated decrease in Na/K-ATPase activity [47]. These effects may be important in the pathogenesis of pulmonary edema. Experimental hypocapnia causes profound acute parenchymal lung injury that may be ameliorated by normalization of alveolar CO<sub>2</sub> by adding inspired CO<sub>2</sub> [48]; it also worsens ischemia–reperfusion-induced lung injury [49].

#### Myocardial and vascular injury

HCA protects the heart following ischemia–reperfusion injury. Reperfusion with a hypercapnia acidotic perfusate enhances recovery of myocardial function following prolonged ischemia *ex vivo* as well as *in vivo* [50]. In experimental polymicrobial sepsis in female sheep, HCA improved tissue oxygenation and reduced lung edema formation more than dobutamine administration [32]. Hypocapnia worsens ischemic injury in the neonatal lamb myocardium [51] and abolishes the protective effects of preconditioning.

#### Central nervous system

Hypercapnia attenuates hypoxic-ischemic brain injury in the immature rat [52] and protects the porcine brain from reoxygenation injury by attenuation of free radical action. Hypercapnia increases the size of the region at risk of infarction in experimental acute focal ischemia; in hypoxic-ischemic injury in the immature rat brain, hypocapnia worsens the histologic magnitude of stroke [52] and is associated with a decrease in CBF to the hypoxia-injured brain as well as disturbance of glucose utilization and phosphate reserves. Hypocapnia during resuscitation increases functional and histologic evidence of brain injury following experimental cardiac arrest in dogs [53]. Hypocapnia further exacerbates the cerebral O<sub>2</sub> supply:demand imbalance by increasing neuronal excitability, increasing excitatory synaptic transmission, and via a direct effect on the neuronal membrane itself

[54]. Severe hypocapnia increases *N*-methyl-D-aspartic acid receptor-mediated neurotoxicity in the newborn piglet and increases neuronal dopamine, particularly in the striatum, which may worsen reperfusion injury, especially in the immature brain [55]. Indeed, hypocapnia may be directly neurotoxic, through increased incorporation of choline into membrane phospholipids [56].

### **Clinical profile of hypocapnia in the critically ill patient**

#### **Potential benefits**

There are some potential benefits of acute hypocapnic alkalosis in specific critically ill patients [57]. For patients who have life-threatening elevations in intracranial pressure, rapid induction of hypocapnia for short durations may prevent brainstem herniation, allowing definitive diagnosis and therapy to be instituted. Hypocapnia may also be indicated in neonates with pulmonary hypertensive crises. The knowledge of the dramatic deleterious effects of hypocapnia on the neonatal brain, together with the known adverse effects of excessive lung stretch, however, have led to the use of alternative measures in this regard. There are very few other situations where hypocapnia is of benefit.

#### **Potential risks**

Hypocapnia may be a pathogenic entity in the setting of critical illness, particularly in ARDS patients. Edmonds and Holm demonstrated more than 30 years ago that alveolar hypocapnia produces hemorrhagic consolidation in the lung, and that attenuation of such adverse effects could be achieved by addition of inhaled CO<sub>2</sub> [48]. In the clinical context, Trimble and colleagues in 1971 demonstrated that hypocapnia increased airway resistance, increased work of breathing, worsened ventilation/perfusion matching, increased the alveolar-arterial O<sub>2</sub> gradient and decreased the partial pressure of O<sub>2</sub> in the blood in ARDS patients, and that administration of CO<sub>2</sub> (that is, therapeutic hypercapnia) improved systemic oxygenation and reduced the shunt fraction [58]. Both hyperventilation and hypocapnia have been identified as *independent* determinants of long-term pulmonary dysfunction in patients with bronchopulmonary dysplasia, as well as being implicated in the pathogenesis of asthma.

In traumatic brain injury, sustained hypocapnia may exacerbate cerebral hypoperfusion. Hypocapnia-induced cerebral vasoconstriction may worsen cerebral vasospasm in these patients, and has been demonstrated to exacerbate pre-existing impairment of CBF and metabolism in patients with traumatic brain injury. Coles and colleagues demonstrated that moderate hypocapnia (<34 mmHg) can significantly reduce global CBF and result in significant increases in the volume of critically

hypoperfused tissue in the injured brain [27]. Prophylactic hyperventilation of head-injured patients, formerly employed in order to reduce intracranial pressure, *worsens* outcome [59]. In children with severe head injury, hypocapnia-induced critical cerebral ischemia has also been demonstrated. In the setting of resuscitation following cardiac arrest, hypocapnia induces cerebral ischemia in the post-resuscitation period [60]. Hypocapnic alkalosis has also been associated with poor prognosis in patients with acute cerebrovascular accidents.

In the critically ill patient, hypocapnia has been clearly linked to the development of arrhythmias, adversely affects the myocardial supply:demand balance [61], increases the risk of coronary vasospasm [62], and may worsen the progression of acute coronary syndromes.

### **Clinical profile of hypercapnia in the critically ill patient**

#### **Potential benefits**

There are no clinical studies of hypercapnia independent of V<sub>T</sub> in mechanical ventilation strategies. Indirect evidence exists in humans, however, for a protective effect of HCA independent of V<sub>T</sub>. Kregenow and colleagues examined mortality as a function of permissive hypercapnia in patients enrolled in the ARDS Network V<sub>T</sub> study [4,8]. Using multivariate logistic regression analysis, and controlling for other co-morbidities and severity of lung injury, they demonstrated that permissive hypercapnia reduced mortality in patients randomized to the higher V<sub>T</sub> (12 ml/kg) [8]. There was, however, no additional protective effect of permissive hypercapnia in patients randomized to receive the lower V<sub>T</sub> (6 ml/kg) [8].

In children with congenital heart disease undergoing cardiopulmonary bypass, blood gas management with a pH-stat strategy, which results in higher PaCO<sub>2</sub> levels, reduces postoperative morbidity [63].

#### **Potential risks**

Rapid induction of hypercapnia in the critically ill patient may have adverse effects. Acute hypercapnia impairs myocardial function. HCA may induce vasoconstriction of the pulmonary vascular bed, leading to right ventricular systolic overload; and in patients with ARDS, HCA may exacerbate hypoxic vasoconstriction. In patients with severe ARDS, HCA – induced by V<sub>T</sub> reduction and increases in positive end-expiratory pressure – impaired right ventricular function and hemodynamics despite positive effects on oxygenation and alveolar recruitment [64]. An adverse effect of hypercapnia on skeletal muscle function, and diaphragmatic function in particular, is a concern.

Hypercapnia-induced increases in CBF and cerebral blood volume may adversely impact on intracranial

pressure in patients with traumatic brain injury. An association between intraventricular hemorrhage and severe, but not mild, hypercapnia has been reported in retrospective studies.

Defining a safe and efficacious threshold of hypercapnia remains an elusive goal. Although beneficial effects, including tissue oxygenation, may have a ceiling level in animals [33], similar findings have not been reported in humans. Evidence of a temporal limit to beneficial effects undermines this concept further – timing (that is, adaptation) may be as important as the degree of severity. Attempts to specify such a value are problematic outside the clinical context. Clinicians must be mindful of the tradeoff between the beneficial and deleterious effects of hypercapnia as outlined, and must tailor treatment in each individual case; for example, in the case of combined lung and head injury, regional monitors of cerebral oxygenation and intracranial pressure may be used to guide therapy.

#### **Therapeutic hypercapnia in the critically ill patient**

Despite extensive effort over the past decade, particularly in the experimental setting, the ideal target population for trials of therapeutic hypercapnia (that is, administration of CO<sub>2</sub> to the ventilator breathing circuit) remains somewhat ill-defined. Given the immunosuppressive effects of HCA, and its potential to retard reparative processes, HCA may ultimately prove its utility as a temporary and brief measure, designed to limit predictable and transient organ injury. In that respect, therapeutic hypercapnia during or immediately post cardiopulmonary bypass would appear to hold some promise. HCA is protective in numerous experimental models of organ ischemia–reperfusion, and recent clinical studies have shown improved systemic oxygenation with the use of therapeutic hypercapnia after bidirectional superior cavopulmonary anastomosis in children [65].

#### **Hypercapnia in the critically ill patient – role of buffering**

In patients managed with protective ventilation strategies, buffering of the acidosis induced by hypercapnia remains a common – albeit controversial – clinical practice. Buffering with sodium bicarbonate was permitted in the ARDS Network V<sub>T</sub> study [4]. The need to consider the effects of buffering HCA is emphasized by the fact that both hypercapnia and acidosis *per se* may exert distinct biologic effects. There is no evidence to support buffering, however, and a number of specific concerns exist regarding this practice. The protective effects of HCA in experimental lung injury are a function of the acidosis, rather than the elevated CO<sub>2</sub> *per se* [66], and therefore buffering may simply ablate any protective effects. In experimental lung injury induced by *E. coli* or

endotoxin, renal buffering of hypercapnia significantly worsened physiological and histological measurements of injury [67].

Specific concerns exist regarding sodium bicarbonate, the buffer used most frequently in the clinical setting. The effectiveness of bicarbonate infusion as a buffer is dependent on the ability to excrete CO<sub>2</sub>, rendering it less effective in buffering HCA. In fact, bicarbonate may further raise PaCO<sub>2</sub> where alveolar ventilation is limited, such as in ARDS. While bicarbonate may correct the arterial pH, it may worsen an intracellular acidosis because the CO<sub>2</sub> produced when bicarbonate reacts with metabolic acids diffuses readily across cell membranes, whereas bicarbonate cannot.

There may be a role for alternative buffers, such as the amino alcohol tromethamine (*tris*-hydroxymethyl aminomethane (THAM)). THAM penetrates cells easily and can buffer pH changes and simultaneously reduce the partial pressure of CO<sub>2</sub> [68]. Unlike bicarbonate, which requires an open system for CO<sub>2</sub> elimination in order to exert its buffering effect, THAM is effective in a closed or semi-closed system [68]. THAM rapidly restores pH and acid–base regulation in acidemia caused by CO<sub>2</sub> retention [68]. In ARDS patients, THAM attenuates the hemodynamic consequences of a rapidly induced HCA.

In summary, if a clinician elects to buffer HCA, the rationale for this practice should be clear – for example, to ameliorate potentially deleterious hemodynamic consequences of acidosis – and THAM should be considered rather than bicarbonate.

#### **Summary and conclusions**

The importance and complexity of inter-relationships between alterations in systemic CO<sub>2</sub> tension and critical illness states is increasingly appreciated. Ventilator strategies involving hypercapnia are widely utilized in the critically ill adult and child, with the aim of realizing the benefits of reduced lung stretch. The potential for hypercapnia to directly contribute to the beneficial effects of protective lung ventilatory strategies is clear from experimental studies demonstrating protective effects in models of acute lung and systemic organ injury. Concerns persist, however, regarding the potential for hypercapnia and/or acidosis to exert deleterious effects, and the need for caution prior to extrapolation to the clinical context must be emphasized.

Hypocapnia is an underappreciated phenomenon in the critically ill patient, and is potentially deleterious, particularly when severe or prolonged. Hypocapnia should be avoided except in specific clinical situations; when induced, hypercapnic acidosis should be for specific indications while definitive measures are undertaken.

A clearer understanding of the effects and mechanisms of action of CO<sub>2</sub> is central to determining its safety and

This article is part of a review series on Gaseous mediators, edited by Peter Radermacher. Other articles in the series can be found online at [http://ccforum.com/series/gaseous\\_mediators](http://ccforum.com/series/gaseous_mediators)

therapeutic utility in the critically ill patient. In the coming years, research efforts should focus on determining the potential mechanisms by which alterations in CO<sub>2</sub> tension contribute to the pathogenesis of acute organ injury states. Such insights should advance our understanding of the situations in which hypercapnia or hypocapnia may be helpful or dangerous, and should guide clinicians with regard to the rational use of CO<sub>2</sub> in the critically ill patient.

#### Abbreviations

ALI, acute lung injury; ARDS, acute respiratory distress syndrome; CBF, cerebral blood flow; CO<sub>2</sub>, carbon dioxide; HCA, hypercapnic acidosis; NF, nuclear factor; O<sub>2</sub>, oxygen; PaCO<sub>2</sub>, partial pressure of carbon dioxide in the blood; THAM, tris-hydroxymethyl aminomethane; TNF, tumor necrosis factor; V<sub>T</sub>, tidal volume.

#### Competing interests

The authors declare that they have no competing interests.

#### Acknowledgements

This manuscript was supported in part by a fellowship from Molecular Medicine Ireland (to GC), and funding from the European Research Council (to JGL) under the Framework 7 program. BPK holds the Dr Geoffrey Barker Chair in Critical Care Medicine, and is supported by the Canadian Institutes for Health Research

#### Author details

<sup>1</sup>Department of Anaesthesia, Clinical Sciences Institute, National University of Ireland, Galway, Ireland. <sup>2</sup>Lung Biology Group, National Centre of Biomedical Engineering Sciences, National University of Ireland, Galway, Ireland. <sup>3</sup>Departments of Critical Care Medicine and Anesthesia and the Program in Physiology and Experimental Medicine, The Hospital for Sick Children, University of Toronto, 555 university Avenue, Toronto, ON M5G 1X8, Canada.

Published: 30 April 2010

#### References

1. Radrizzani D, Iapichino G: **Nutrition and lung function in the critically ill patient.** *Clin Nutr* 1998, **17**:7-10.
2. Marion DW, Spiegel TP: **Changes in the management of severe traumatic brain injury: 1991-1997.** *Crit Care Med* 2000, **28**:16-18.
3. Drummond WH, Gegory GA, Heymann MA, Phibbs RA: **The independent effects of hyperventilation, tolazoline, and dopamine on infants with persistent pulmonary hypertension.** *J Pediatr* 1981, **98**:603-611.
4. **Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network.** *N Engl J Med* 2000, **342**:1301-1308.
5. Hickling KG, Walsh J, Henderson S, Jackson R: **Low mortality rate in adult respiratory distress syndrome using low-volume, pressure-limited ventilation with permissive hypercapnia: a prospective study.** *Crit Care Med* 1994, **22**:1568-1578.
6. Wung JT, James LS, Kilchevsky E, James E: **Management of infants with severe respiratory failure and persistence of the fetal circulation, without hyperventilation.** *Pediatrics* 1985, **76**:488-494.
7. Darioli R, Perret C: **Mechanical controlled hypoventilation in status asthmaticus.** *Am Rev Respir Dis* 1984, **129**:385-387.
8. Kregenzow DA, Rubenfeld GD, Hudson LD, Swenson ER: **Hypercapnic acidosis and mortality in acute lung injury.** *Crit Care Med* 2006, **34**:1-7.
9. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: **Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.** *Chest* 1992, **101**:1644-1655.

10. Glaser N, Barnett P, McCaslin I, Nelson D, Trainor J, Louie J, Kaufman F, Quayle K, Roback M, Malley R, Kuppermann N: **Risk factors for cerebral edema in children with diabetic ketoacidosis.** The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. *N Engl J Med* 2001, **344**:264-269.
11. Neumann JO, Chambers IR, Citerio G, Enblad P, Gregson BA, Howells T, Mattern J, Nilsson P, Piper I, Ragauskas A, Sahuquillo J, Yau YH, Kiening K: **The use of hyperventilation therapy after traumatic brain injury in Europe: an analysis of the BrainIT database.** *Intensive Care Med* 2008, **34**:1676-1682.
12. Curry R, Hollingworth W, Ellenbogen RG, Vavilala MS: **Incidence of hypo- and hypercarbia in severe traumatic brain injury before and after 2003 pediatric guidelines.** *Pediatr Crit Care Med* 2008, **9**:141-146.
13. Forster HV, Martino P, Hodges M, Krause K, Bonis J, Davis S, Pan L: **The carotid chemoreceptors are a major determinant of ventilatory CO<sub>2</sub> sensitivity and of PaCO<sub>2</sub> during eupneic breathing.** *Adv Exp Med Biol* 2008, **605**:322-326.
14. Putnam RW, Filosa JA, Ritucci NA: **Cellular mechanisms involved in CO<sub>2</sub> and acid signaling in chemosensitive neurons.** *Am J Physiol Cell Physiol* 2004, **287**:C1493-C1526.
15. Borison HL, Hurst JH, McCarthy LE, Rosenstein R: **Arterial hydrogen ion versus CO<sub>2</sub> on depth and rate of breathing in decerebrate cats.** *Respir Physiol* 1977, **30**:311-325.
16. Chen Y, Cann MJ, Litvin TN, Iourgenko V, Sinclair ML, Levin LR, Buck J: **Soluble adenylyl cyclase as an evolutionarily conserved bicarbonate sensor.** *Science* 2000, **289**:625-628.
17. Summers BA, Overholt JL, Prabhakar NR: **CO<sub>2</sub> and pH independently modulate L-type Ca<sup>2+</sup> current in rabbit carotid body glomus cells.** *J Neurophysiol* 2002, **88**:604-612.
18. Takeshita K, Suzuki Y, Nishio K, Takeuchi O, Toda K, Kudo H, Miyao N, Ishii M, Sato N, Naoki K, Aoki T, Suzuki K, Hiraoka R, Yamaguchi K: **Hypercapnic acidosis attenuates endotoxin-induced nuclear factor- $\kappa$ B activation.** *Am J Respir Cell Mol Biol* 2003, **29**:124-132.
19. O'Toole D, Hassett P, Contreras M, Higgins BD, McKeown ST, McAuley DF, O'Brien T, Laffey JG: **Hypercapnic acidosis attenuates pulmonary epithelial wound repair by an NF- $\kappa$ B dependent mechanism.** *Thorax* 2009, **64**:976-982.
20. Domino KB, Emery MJ, Swenson ER, Hlastala MP: **Ventilation heterogeneity is increased in hypocapnic dogs but not pigs.** *Respir Physiol* 1998, **111**:89-100.
21. Rodarte JR, Hyatt RE: **Effect of acute exposure to CO<sub>2</sub> on lung mechanics in normal man.** *Respir Physiol* 1973, **17**:135-145.
22. Traystman RJ, Terry PB, Menkes HA: **Carbon dioxide - a major determinant of collateral ventilation.** *J Appl Physiol* 1978, **45**:69-74.
23. Emery MJ, Eveland RL, Kim SS, Hildebrandt J, Swenson ER: **CO<sub>2</sub> relaxes parenchyma in the liquid-filled rat lung.** *J Appl Physiol* 2007, **103**:710-716.
24. Domino KB, Swenson ER, Polissar NL, Lu Y, Eisenstein BL, Hlastala MP: **Effect of inspired CO<sub>2</sub> on ventilation and perfusion heterogeneity in hyperventilated dogs.** *J Appl Physiol* 1993, **75**:1306-1314.
25. Grubb RL, Jr, Raichle ME, Eichling JO, Ter-Pogossian MM: **The effects of changes in PaCO<sub>2</sub> on cerebral blood volume, blood flow, and vascular mean transit time.** *Stroke* 1974, **5**:630-639.
26. Alexander SC, Smith TC, Strobel G, Stephen GW, Wollman H: **Cerebral carbohydrate metabolism of man during respiratory and etabolic alkalosis.** *J Appl Physiol* 1968, **24**:66-72.
27. Coles JP, Fryer TD, Coleman MR, Smielewski P, Gupta AK, Minhas PS, Aigbirhio F, Chatfield DA, Williams GB, Boniface S, Carpenter TA, Clark JC, Pickard JD, Menon DK: **Hyperventilation following head injury: effect on ischemic burden and cerebral oxidative metabolism.** *Crit Care Med* 2007, **35**:568-578.
28. Cullen DJ, Eger EI, 2nd: **Cardiovascular effects of carbon dioxide in man.** *Anesthesiology* 1974, **41**:345-349.
29. Ratnaraj J, Kabon B, Talcott MR, Sessler DI, Kurz A: **Supplemental oxygen and carbon dioxide each increase subcutaneous and intestinal intramural oxygenation.** *Anesth Analg* 2004, **99**:207-211.
30. Akca O, Doufas AG, Morioka N, Iscoe S, Fisher J, Sessler DI: **Hypercapnia improves tissue oxygenation.** *Anesthesiology* 2002, **97**:801-806.
31. Akca O, Sessler DI, Delong D, Keijner R, Ganzel B, Doufas AG: **Tissue oxygenation response to mild hypercapnia during cardiopulmonary bypass with constant pump output.** *Br J Anaesth* 2006, **96**:708-714.
32. Wang Z, Su F, Bruhn A, Yang X, Vincent JL: **Acute hypercapnia improves indices of tissue oxygenation more than dobutamine in septic shock.** *Am J Respir Crit Care Med* 2008, **177**:178-183.

33. Komori M, Takada K, Tomizawa Y, Nishiyama K, Kawamata M, Ozaki M: **Permissive range of hypercapnia for improved peripheral microcirculation and cardiac output in rabbits.** *Crit Care Med* 2007, **35**:2171-2175.
34. Hillered L, Ernster L, Siesjo BK: **Influence of in vitro lactic acidosis and hypercapnia on respiratory activity of isolated rat brain mitochondria.** *J Cereb Blood Flow Metab* 1984, **4**:430-437.
35. Sinclair SE, Kregenow DA, Lamm WJ, Starr IR, Chi EY, Hlastala MP: **Hypercapnic acidosis is protective in an in vivo model of ventilator-induced lung injury.** *Am J Respir Crit Care Med* 2002, **166**:403-408.
36. Laffey JG, Engelberts D, Duggan M, Veldhuizen R, Lewis JF, Kavanagh BP: **Carbon dioxide attenuates pulmonary impairment resulting from hyperventilation.** *Crit Care Med* 2003, **31**:2634-2640.
37. Rai S, Engelberts D, Laffey JG, Frevert C, Kajikawa O, Martin TR, Post M, Kavanagh BP: **Therapeutic hypercapnia is not protective in the in vivo surfactant-depleted rabbit lung.** *Pediatr Res* 2004, **55**:42-49.
38. Ooi H, Cadogan E, Sweeney M, Howell K, O'Regan RG, McLoughlin P: **Chronic hypercapnia inhibits hypoxic pulmonary vascular remodeling.** *Am J Physiol Heart Circ Physiol* 2000, **278**:H331-H338.
39. Kantores C, McNamara PJ, Teixeira L, Engelberts D, Murthy P, Kavanagh BP, Jankov RP: **Therapeutic hypercapnia prevents chronic hypoxia-induced pulmonary hypertension in the newborn rat.** *Am J Physiol Lung Cell Mol Physiol* 2006, **291**:L912-L922.
40. Masood A, Yi M, Lau M, Belcastro R, Shek S, Pan J, Kantores C, McNamara PJ, Kavanagh BP, Belik J, Jankov RP, Tanswell AK: **Therapeutic effects of hypercapnia on chronic lung injury and vascular remodeling in neonatal rats.** *Am J Physiol Lung Cell Mol Physiol* 2009, **297**:L920-L930.
41. Ni Chonghaile M, Higgins BD, Costello JF, Laffey JG: **Hypercapnic acidosis attenuates severe acute bacterial pneumonia-induced lung injury by a neutrophil-independent mechanism.** *Crit Care Med* 2008, **36**:3135-3144.
42. Ni Chonghaile M, Higgins BD, Costello J, Laffey JG: **Hypercapnic acidosis attenuates lung injury induced by established bacterial pneumonia.** *Anesthesiology* 2008, **109**:837-848.
43. O'Croinin DF, Nichol AD, Hopkins N, Boylan J, O'Brien S, O'Connor C, Laffey JG, McLoughlin P: **Sustained hypercapnic acidosis during pulmonary infection increases bacterial load and worsens lung injury.** *Crit Care Med* 2008, **36**:2128-2135.
44. Costello J, Higgins B, Contreras M, Chonghaile MN, Hassett P, O'Toole D, Laffey JG: **Hypercapnic acidosis attenuates shock and lung injury in early and prolonged systemic sepsis.** *Crit Care Med* 2009, **37**:2412-2420.
45. Higgins BD, Costello J, Contreras M, Hassett P, D OT, Laffey JG: **Differential effects of buffered hypercapnia versus hypercapnic acidosis on shock and lung injury induced by systemic sepsis.** *Anesthesiology* 2009, **111**:1317-1326.
46. Briva A, Vadasz I, Lecuona E, Welch LC, Chen J, Dada LA, Trejo HE, Dumasius V, Azzam ZS, Myrianthefs PM, Battle D, Gruenbaum Y, Sznajder JI: **High CO<sub>2</sub> levels impair alveolar epithelial function independently of pH.** *PLoS One* 2007, **2**:e1238.
47. Myrianthefs PM, Briva A, Lecuona E, Dumasius V, Rutschman DH, Ridge KM, Baltopoulos GJ, Sznajder JI: **Hypocapnic but not metabolic alkalosis impairs alveolar fluid reabsorption.** *Am J Respir Crit Care Med* 2005, **171**:1267-1271.
48. Edmunds LH, Jr, Holm JC: **Effect of inhaled CO<sub>2</sub> on hemorrhagic consolidation due to unilateral pulmonary arterial ligation.** *J Appl Physiol* 1969, **26**:710-715.
49. Laffey JG, Engelberts D, Kavanagh BP: **Injurious effects of hypocapnic alkalosis in the isolated lung.** *Am J Respir Crit Care Med* 2000, **162**(2 Pt 1):399-405.
50. Kitakaze M, Takashima S, Funaya H, Minamino T, Node K, Shinozaki Y, Mori H, Hori M: **Temporary acidosis during reperfusion limits myocardial infarct size in dogs.** *Am J Physiol* 1997, **272**(5 Pt 2):H2071-H2078.
51. Nomura F, Aoki M, Forbess JM, Mayer JE, Jr: **Effects of hypercarbic acidotic reperfusion on recovery of myocardial function after cardioplegic ischemia in neonatal lambs.** *Circulation* 1994, **90**(5 Pt 2):II321-II327.
52. Vannucci RC, Towfighi J, Heitjan DF, Brucklacher RM: **Carbon dioxide protects the perinatal brain from hypoxic-ischemic damage: an experimental study in the immature rat.** *Pediatrics* 1995, **95**:868-874.
53. Safar P, Xiao F, Radovsky A, Tanigawa K, Ebmeyer U, Bircher N, Alexander H, Stezoski SW: **Improved cerebral resuscitation from cardiac arrest in dogs with mild hypothermia plus blood flow promotion.** *Stroke* 1996, **27**:105-113.
54. Huttunen J, Tolvanen H, Heinonen E, Voipio J, Wikstrom H, Ilmoniemi RJ, Hari R, Kaila K: **Effects of voluntary hyperventilation on cortical sensory responses. Electroencephalographic and magnetoencephalographic studies.** *Exp Brain Res* 1999, **125**:248-254.
55. Pastuszko P, Wilson DF: **Activation of tyrosine hydroxylase in striatum of newborn piglets in response to hypocapnic ischemia and recovery.** *Adv Exp Med Biol* 1997, **411**:65-73.
56. Mykita S, Golly F, Dreyfus H, Freysz L, Massarelli R: **Effect of CDP-choline on hypocapnic neurons in culture.** *J Neurochem* 1986, **47**:223-231.
57. Laffey JG, Kavanagh BP: **Hypocapnia.** *N Engl J Med* 2002, **347**:43-53.
58. Trimble C, Smith DE, Rosenthal MH, Fosburg RG: **Pathophysiologic role of hypocarbia in post-traumatic pulmonary insufficiency.** *Am J Surg* 1971, **122**:633-638.
59. Muizelaar JP, Marmarou A, Ward JD, Kontos HA, Choi SC, Becker DP, Gruemer H, Young HF: **Adverse effects of prolonged hyperventilation in patients with severe head injury: a randomized clinical trial.** *J Neurosurg* 1991, **75**:731-739.
60. Buunk G, van der Hoeven JG, Meinders AE: **Cerebrovascular reactivity in comatose patients resuscitated from a cardiac arrest.** *Stroke* 1997, **28**:1569-1573.
61. Yokoyama I, Inoue Y, Kinoshita T, Itoh H, Kanno I, Iida H: **Heart and brain circulation and CO<sub>2</sub> in healthy men.** *Acta Physiol (Oxf)* 2008, **193**:303-308.
62. Hirano Y, Ozasa Y, Yamamoto T, Uehara H, Yamada S, Nakagawa K, Ikawa H, Ishikawa K: **Hyperventilation and cold-pressor stress echocardiography for noninvasive diagnosis of coronary artery spasm.** *J Am Soc Echocardiogr* 2001, **14**:626-633.
63. du Plessis AJ, Jonas RA, Wypij D, Hickey PR, Riviello J, Wessel DL, Roth SJ, Burrows FA, Walter G, Farrell DM, Walsh AZ, Plumb CA, del Nido P, Burke RP, Castaneda AR, Mayer JE, Jr, Newburger JW: **Perioperative effects of alpha-stat versus pH-stat strategies for deep hypothermic cardiopulmonary bypass in infants.** *J Thorac Cardiovasc Surg* 1997, **114**:991-1000; discussion 1000-1001.
64. Mekontso Dessap A, Charron C, Devaquet J, Aboab J, Jardin F, Brochard L, Vieillard-Baron A: **Impact of acute hypercapnia and augmented positive end-expiratory pressure on right ventricle function in severe acute respiratory distress syndrome.** *Intensive Care Med* 2009, **35**:1850-1858.
65. Li J, Hoskote A, Hickey C, Stephens D, Bohn D, Holtby H, Van Arsdell G, Redington AN, Adatia I: **Effect of carbon dioxide on systemic oxygenation, oxygen consumption, and blood lactate levels after bidirectional superior cavopulmonary anastomosis.** *Crit Care Med* 2005, **33**:984-989.
66. Laffey JG, Engelberts D, Kavanagh BP: **Buffering hypercapnic acidosis worsens acute lung injury.** *Am J Respir Crit Care Med* 2000, **161**:141-146.
67. Nichol AD, O'Croinin DF, Howell K, Naughton F, O'Brien S, Boylan J, O'Connor C, O'Toole D, Laffey JG, McLoughlin P: **Infection-induced lung injury is worsened after renal buffering of hypercapnic acidosis.** *Crit Care Med* 2009, **37**:2953-2961.
68. Nahas GG, Sutin KM, Fermon C, Streat S, Wiklund L, Wahlander S, Yellin P, Brasch H, Kanchuger M, Capan L, Manne J, Helwig H, Gaab M, Pfenninger E, Wetterberg T, Holmdahl M, Turndorf H: **Guidelines for the treatment of acidemia with THAM.** *Drugs* 1998, **55**:191-224.

doi:10.1186/cc8926

Cite this article as: Curley G, et al.: Bench-to-bedside review: Carbon dioxide. *Critical Care* 2010, **14**:220.